Edymax Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-12-2024
- Paid Up Capital ₹ 0.50 M
as on 23-12-2024
- Company Age 7 Year, 15 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.40 M
as on 23-12-2024
- Revenue 68.74%
(FY 2022)
- Profit 9.47%
(FY 2022)
- Ebitda 91.54%
(FY 2022)
- Net Worth 38.49%
(FY 2022)
- Total Assets 44.32%
(FY 2022)
About Edymax Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.40 M.
Sudhir Singal and Sahil Singal serve as directors at the Company.
- CIN/LLPIN
U24290CH2017PTC041809
- Company No.
041809
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Dec 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Edymax Lifesciences Private Limited offer?
Edymax Lifesciences Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Antibiotic Injection, Nutraceuticals & Dietary Supplements, Vitamin & Multivitamin Injections, Pain Relief Drugs & Pharmaceuticals, Pain Reliever Gel, Mineral Supplement, Ayurvedic,Herbal Products & Medicine, Herbal Oil.
Who are the key members and board of directors at Edymax Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudhir Singal  | Director | 24-Aug-2018 | Current |
| Sahil Singal | Director | 15-Jun-2021 | Current |
Financial Performance of Edymax Lifesciences.
Edymax Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 68.74% increase. The company also saw a slight improvement in profitability, with a 9.47% increase in profit. The company's net worth Soared by an impressive increase of 38.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Edymax Lifesciences?
In 2022, Edymax Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Karnataka Bank Ltd. Creation Date: 11 Jul 2022 | ₹2.40 M | Open |
How Many Employees Work at Edymax Lifesciences?
Unlock and access historical data on people associated with Edymax Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Edymax Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Edymax Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
